Denials, Delays and Deep Discounts in Pharmaceutical Launch

FDA approval is no longer the finish line in the race to product launch success. Access and adoption have risen to the forefront as a major post-approval hurdle: recent research from Syneos Health Consulting’s Value and Access team shows that less than half of newly approved drugs appeared on formulary in their launch year. So what’s a drug developer to do?Co-authors of the report on insurance coverage of new drugs at launch Jeff Stewart, Brian Cotten and Heather Martin discuss the results of...